The c-mesenchymal-epithelia transform factor (c-Met) was first discovered in the 1980s as an oncogene and hepatocyte growth facter (HGF) was identified as the only one ligand of c-Met.HGF induces cells mitogenesis, motogenesis, angiogenesis and morphogenesis.The dysregulation of HGF/Met pathway has been implicated in several cancers.Therefore, development of targeting agents to components in HGF/c-Met pathway is a potential cancer therapeutic strategy.